- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that ...

Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth ...

Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having generated the necessary clinical and tr ...

Core Insights - Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, highlighting its commitment to developing innovative cancer therapies [1][2] Group 1: Presentation Highlights - The presentation titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies" was delivered by Dr. Jonathan Davis, showcasing Helix's leadership in ADC technology [2] - CEACAM6 was identified as a promising therapeutic target due to its high expression in various epithelial cancers, association with poor clinical outcomes, and limited presence in healthy tissues [3] - Data presented demonstrated the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, supporting the development of next-generation ADCs that minimize off-target effects while delivering potent therapeutic payloads [3][4] Group 2: Company Pipeline and Innovations - Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, is designed to enhance the sensitivity of CEACAM6-expressing tumors to therapy and has shown favorable safety and clinical activity in Phase I/II studies for non-small cell lung cancer (NSCLC) [6] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration [6]

Palvella Therapeutics (NasdaqCM:PVLA) Update / briefing February 24, 2026 08:00 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorBohan Wei - VP of Corporate Development and New Product PlanningCatherine Novack - Director of Healthcare Equity ResearchGraig Suvannavejh - Managing DirectorJeff Martini - Chief Scientific OfficerJosh Schimmer - Managing DirectorMichael Kelly - Pediatric Hematologist-OncologistWes Kaupinen - Founder and CEOConference Call ParticipantsAlbert Lowe - Senior Equity Researc ...

Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophyHOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration (FDA) in support of the ongoing BLA review SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clini ...

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, ...

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9 ...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than Apr ...

February 24, 2026 Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar ...